Abstract
Due to the failure of chemotherapy and the only available vaccine, BCG, to control tuberculosis (TB) disease, there is an urgent need to develop new vaccines and therapeutics. The identification of correlates of immune protection or “biomarkers” will facilitate the rational design of vaccines and drugs for the prevention and clearance of TB infection. Although it is known that IFN-γ is essential for protective immunity, animal and human studies have found that IFN-γ alone is not sufficient for the prevention of TB disease. There is evidence that IL-23, a recently described member of the IL-12 family of cytokines, is important in the immuno-pathogenesis of TB. There is also evidence that regulatory T cells (Treg) are present in TB disease and that Treg may suppress effector T cell responses. In the last five years, clinical studies have been able to use Mycobacterium tuberculosis specific antigens, such as ESAT-6, to focus on recently infected, healthy contacts of TB patients in endemic countries. Advances in techniques such as multi-parameter flow cytometry and DNA microarray analysis will enable us to study these cohorts in great detail and facilitate the identification of immune correlates for the rational design of drugs and vaccines for the treatment and prevention of TB.
Keywords: Tuberculosis, correlate, biomarker, IFN-gamma, IL-4, IL-12, IL-23, FoxP3
Current Molecular Medicine
Title: Correlates of Immune Protection from Tuberculosis
Volume: 7 Issue: 3
Author(s): Helen A. Fletcher
Affiliation:
Keywords: Tuberculosis, correlate, biomarker, IFN-gamma, IL-4, IL-12, IL-23, FoxP3
Abstract: Due to the failure of chemotherapy and the only available vaccine, BCG, to control tuberculosis (TB) disease, there is an urgent need to develop new vaccines and therapeutics. The identification of correlates of immune protection or “biomarkers” will facilitate the rational design of vaccines and drugs for the prevention and clearance of TB infection. Although it is known that IFN-γ is essential for protective immunity, animal and human studies have found that IFN-γ alone is not sufficient for the prevention of TB disease. There is evidence that IL-23, a recently described member of the IL-12 family of cytokines, is important in the immuno-pathogenesis of TB. There is also evidence that regulatory T cells (Treg) are present in TB disease and that Treg may suppress effector T cell responses. In the last five years, clinical studies have been able to use Mycobacterium tuberculosis specific antigens, such as ESAT-6, to focus on recently infected, healthy contacts of TB patients in endemic countries. Advances in techniques such as multi-parameter flow cytometry and DNA microarray analysis will enable us to study these cohorts in great detail and facilitate the identification of immune correlates for the rational design of drugs and vaccines for the treatment and prevention of TB.
Export Options
About this article
Cite this article as:
Fletcher A. Helen, Correlates of Immune Protection from Tuberculosis, Current Molecular Medicine 2007; 7 (3) . https://dx.doi.org/10.2174/156652407780598520
DOI https://dx.doi.org/10.2174/156652407780598520 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Health Benefits of Manuka Honey as an Essential Constituent for Tissue Regeneration
Current Drug Metabolism The Expanding Universe of γ δ T Lymphocytes: Subsets, Generation and Function
Current Immunology Reviews (Discontinued) Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Applications of Neural Networks in the Medicinal Chemistry Field
Current Medicinal Chemistry - Central Nervous System Agents The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Neglected Diseases - New Compounds and Treatments
Current Medicinal Chemistry Tuberculosis: Current Status, Diagnosis, Treatment and Development of Novel Vaccines
Current Pharmaceutical Biotechnology Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Efflux Pumps of Gram-Negative Bacteria, a New Target for New Molecules
Current Topics in Medicinal Chemistry Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry Targeting the Peptide Deformylase of Mycobacterium tuberculosis Leads to Drug Discovery
Letters in Drug Design & Discovery Liposome Technology for Drug Delivery Against Mycobacterial Infections
Current Pharmaceutical Design An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design Inhalation Delivery of Protein Therapeutics
Inflammation & Allergy - Drug Targets (Discontinued) The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics